High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis.

BACKGROUND AND AIMS The epidermal growth factor receptor (EGFR) has been recognized as a molecular target for antibody-based therapy in various cancer types. Here we aimed to analyze the relation between high expression of EGFR and postoperational survival in patients with colon cancer. METHODS A meta-analysis was performed by searching PubMed, Cochrane Library, EMBASE, and Science Direct databases from 1960 to June 2012. Data were extracted from studies comparing survival in colon cancer patients having higher EGFR expression with those having lower levels. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. RESULTS Four studies including 815 colon cancer patients were subjected to final analysis. Comparing to patients with low expression of EGFR, the HR of postoperational survival for patients with high EGFR expression was 2.34 (95% CI: 1.83-2.99), which could significantly predict poorer survival. CONCLUSIONS High expression of EGFR might predict poor survival for patients with colon cancer.

[1]  Y. Toiyama,et al.  Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. , 2009, Oncology reports.

[2]  G. Tortora,et al.  Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer , 2012, Cancer.

[3]  Dongyun Yang,et al.  Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. , 2008, Cancer research.

[4]  R. Palmqvist,et al.  Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer , 2011, International journal of cancer.

[5]  F. Ciardiello,et al.  Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery , 2006, Annals of Surgical Oncology.

[6]  K. Shirouzu,et al.  Amphiregulin is a prognostic factor in colorectal cancer. , 2012, Anticancer research.

[7]  C. Tournigand,et al.  From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. , 2011, Seminars in oncology.

[8]  M. Saif.  Targeted agents for adjuvant therapy of colon cancer. , 2006, Clinical colorectal cancer.

[9]  An-Ting T. Lu,et al.  Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. , 2011, Clinical colorectal cancer.

[10]  A. P. Majumdar,et al.  Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. , 2010, Anticancer research.

[11]  L. Desantis,et al.  Travoprost: a potent ocular hypotensive agent. , 2003, Drugs of today.

[12]  H. Lenz,et al.  Molecular predictive and prognostic markers in colon cancer. , 2010, Cancer treatment reviews.

[13]  D. Threadgill,et al.  Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer , 2012, Cancer biology & therapy.

[14]  A. Khorana,et al.  Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma , 2003, Cancer.

[15]  S. Barni,et al.  Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies , 2012, Expert opinion on drug safety.

[16]  D. Sargent,et al.  Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status , 2009, British Journal of Cancer.

[17]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[19]  A. Villanueva,et al.  Signaling Pathways in Hepatocellular Carcinoma , 2011, Oncology.

[20]  Hongwei Zhang,et al.  The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas , 2010, Expert opinion on biological therapy.

[21]  C. Tournigand,et al.  Stage II and Stage III Colon Cancer: Treatment Advances and Future Directions , 2010, Cancer journal.

[22]  Gang Wu,et al.  EGFR mutations in non‐small‐cell lung cancer among smokers and non‐smokers: A meta‐analysis , 2012, Environmental and molecular mutagenesis.

[23]  Hongwei Zhang,et al.  Angiogenesis-related molecular targets in esophageal cancer , 2011, Expert opinion on investigational drugs.